Spero Therapeutics (NASDAQ:SPRO) Receives “Hold” Rating from TD Cowen

TD Cowen restated their hold rating on shares of Spero Therapeutics (NASDAQ:SPRO) in a report released on Monday morning, Marketbeat Ratings reports.

SPRO has been the subject of several other research reports. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Spero Therapeutics in a report on Friday, November 15th. HC Wainwright lowered their price target on shares of Spero Therapeutics from $7.00 to $5.00 and set a “buy” rating for the company in a report on Monday, November 4th.

Spero Therapeutics Trading Up 3.4 %

NASDAQ SPRO opened at $1.20 on Monday. The firm has a market cap of $65.42 million, a price-to-earnings ratio of 17.15 and a beta of 0.63. The company has a 50 day moving average of $1.28 and a 200-day moving average of $1.36. Spero Therapeutics has a 1-year low of $1.01 and a 1-year high of $1.89.

Hedge Funds Weigh In On Spero Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Virtu Financial LLC acquired a new stake in shares of Spero Therapeutics during the first quarter worth $31,000. Renaissance Technologies LLC boosted its holdings in shares of Spero Therapeutics by 14.2% during the 2nd quarter. Renaissance Technologies LLC now owns 975,952 shares of the company’s stock worth $1,269,000 after buying an additional 121,492 shares during the period. Acadian Asset Management LLC boosted its holdings in Spero Therapeutics by 121.8% in the 1st quarter. Acadian Asset Management LLC now owns 762,598 shares of the company’s stock valued at $1,310,000 after purchasing an additional 418,742 shares during the period. Murchinson Ltd. lifted its holdings in shares of Spero Therapeutics by 1.3% during the 1st quarter. Murchinson Ltd. now owns 873,910 shares of the company’s stock worth $1,503,000 after acquiring an additional 11,210 shares during the period. Finally, Vanguard Group Inc. increased its position in Spero Therapeutics by 0.6% during the 1st quarter. Vanguard Group Inc. now owns 1,653,432 shares of the company’s stock worth $2,844,000 after purchasing an additional 9,675 shares in the last quarter. 25.60% of the stock is owned by institutional investors.

About Spero Therapeutics

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.